Crescent Biopharma, Inc. also files under CBIO; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Buy(P) | 853K | $14.50 | $12.4M |
| Jul 16, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Buy(P) | 526K | $14.50 | $7.6M |
| Jun 22, 2026 | Brumm Joshua T | Chief Executive Officer, Director | Sell(S) | 42K | $17.99 | $761K |
| Jun 22, 2026 | Bispham Barbara Harlin | See Remarks | Sell(S) | 1K | $17.99 | $22K |
| Jun 22, 2026 | Lynch Ryan | See Remarks | Sell(S) | 465 | $17.99 | $8K |
| Jun 22, 2026 | Pinkas Jan | Chief Scientific Officer | Sell(S) | 1K | $17.99 | $23K |
| Jun 22, 2026 | Im Ellie Eunkyung | Chief Medical Officer | Sell(S) | 1K | $17.99 | $22K |
| Jun 22, 2026 | Scalzo Richard William | Chief Financial Officer | Sell(S) | 1K | $17.99 | $20K |
| Jun 22, 2026 | McNeill Jonathan | President and COO | Sell(S) | 21K | $17.99 | $370K |
| Jun 2, 2026 | Violin Jonathan | Director | Grant(A) | 11K | — | $0 |
| Jun 2, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Grant(A) | 11K | — | $0 |
| Jun 2, 2026 | Balcom Alexandra | Director | Grant(A) | 11K | — | $0 |
| Jun 2, 2026 | Lubner David Charles | Director | Grant(A) | 11K | — | $0 |
| Jun 2, 2026 | Moran Susan | Director | Grant(A) | 11K | — | $0 |
| Dec 15, 2025 | Doughty Christopher Grant | Chief Business Officer | Grant(A) | 59K | — | $0 |
| Dec 15, 2025 | Doughty Christopher Grant | Chief Business Officer | Grant(A) | 15K | — | — |
| Dec 15, 2025 | Lynch Ryan | See Remarks | Grant(A) | 4K | — | — |
| Dec 15, 2025 | Brumm Joshua T | Chief Executive Officer, Director | Grant(A) | 10K | — | — |
| Dec 15, 2025 | Brumm Joshua T | Chief Executive Officer, Director | Grant(A) | 45K | — | — |
| Dec 15, 2025 | Scalzo Richard William | Chief Financial Officer | Grant(A) | 58K | — | $0 |
| Dec 15, 2025 | Bispham Barbara Harlin | See Remarks | Grant(A) | 72K | — | $0 |
| Dec 15, 2025 | Scalzo Richard William | Chief Financial Officer | Grant(A) | 5K | — | — |
| Dec 15, 2025 | Bispham Barbara Harlin | See Remarks | Grant(A) | 12K | — | — |
| Dec 15, 2025 | Scalzo Richard William | Chief Financial Officer | Grant(A) | 14K | — | — |
| Dec 15, 2025 | Lynch Ryan | See Remarks | Grant(A) | 8K | — | — |
| Dec 15, 2025 | Brumm Joshua T | Chief Executive Officer, Director | Grant(A) | 180K | — | $0 |
| Dec 15, 2025 | McNeill Jonathan | President and COO | Grant(A) | 78K | — | $0 |
| Dec 15, 2025 | Doughty Christopher Grant | Chief Business Officer | Grant(A) | 8K | — | — |
| Dec 15, 2025 | Lynch Ryan | See Remarks | Grant(A) | 34K | — | $0 |
| Dec 15, 2025 | Pinkas Jan | Chief Scientific Officer | Grant(A) | 5K | — | — |
| Dec 15, 2025 | McNeill Jonathan | President and COO | Grant(A) | 6K | — | — |
| Dec 15, 2025 | Bispham Barbara Harlin | See Remarks | Grant(A) | 6K | — | — |
| Dec 15, 2025 | McNeill Jonathan | President and COO | Grant(A) | 20K | — | — |
| Dec 15, 2025 | Im Ellie Eunkyung | Chief Medical Officer | Grant(A) | 65K | — | $0 |
| Dec 15, 2025 | Im Ellie Eunkyung | Chief Medical Officer | Grant(A) | 5K | — | — |
| Dec 15, 2025 | Im Ellie Eunkyung | Chief Medical Officer | Grant(A) | 16K | — | — |
| Dec 15, 2025 | Pinkas Jan | Chief Scientific Officer | Grant(A) | 70K | — | $0 |
| Dec 15, 2025 | Pinkas Jan | Chief Scientific Officer | Grant(A) | 18K | — | — |
| Dec 8, 2025 | McNeill Jonathan | President and COO | Grant(A) | 173K | — | $0 |
| Dec 8, 2025 | Brumm Joshua T | Chief Executive Officer, Director | Grant(A) | 346K | — | $0 |
| Dec 4, 2025 | Harwin Peter Evan | Director, 10% Owner | Buy(P) | 131K | $13.41 | $1.8M |
| Dec 4, 2025 | Harwin Peter Evan | Director, 10% Owner | Buy(P) | 1.4M | $13.41 | $18.2M |
| Jul 16, 2025 | Pinkas Jan | Chief Scientific Officer | Grant(A) | 142K | — | $0 |
| Jun 23, 2025 | Harwin Peter Evan | Director, 10% Owner | Grant(A) | 9K | — | $0 |
| Jun 23, 2025 | Moran Susan | Director | Grant(A) | 9K | — | $0 |
| Jun 23, 2025 | Violin Jonathan | Director | Grant(A) | 9K | — | $0 |
| Jun 23, 2025 | Balcom Alexandra | Director | Grant(A) | 9K | — | $0 |
| Jun 23, 2025 | Lubner David Charles | Director | Grant(A) | 9K | — | $0 |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 304K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 557K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 56K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 258K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 26K | — | — |
| Jun 13, 2025 | BVF GP Holdings LLC | 10% Owner | Other(J) | 657K | — | — |
| Aug 8, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 261K | $0.19 | $50K |
| Aug 7, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 61K | $0.18 | $11K |
| Aug 6, 2024 | Invus Public Equities Advisors, LLC | 10% Owner | Sell(S) | 56K | $0.18 | $10K |
| Aug 5, 2024 | Invus Public Equities Advisors, LLC | 10% Owner | Sell(S) | 165K | $0.19 | $31K |
| Aug 2, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 286K | $0.20 | $57K |
| Aug 1, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 64K | $0.22 | $14K |
| Jul 30, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 757K | $0.22 | $167K |
| Jul 29, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 364K | $0.24 | $87K |
| Jul 26, 2024 | Siren, L.L.C. | 10% Owner | Sell(S) | 258K | $0.24 | $62K |
| Jun 21, 2024 | Rock Edwin | Chief Medical Officer | Buy(P) | 115K | $0.27 | $31K |
| Jun 20, 2024 | Rock Edwin | Chief Medical Officer | Buy(P) | 190K | $0.25 | $48K |
| Jun 18, 2024 | Hahn Brian M. | SVP Finance, CFO | Buy(P) | 18K | $0.25 | $4K |
| May 1, 2024 | Goldberg Mark Alan | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Pearson Timothy R | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | King Rachel K. | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Andrews Patricia S | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Jackson Scott Thomas | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Junius Daniel M | Director | Grant(A) | 40K | — | $0 |
| May 1, 2024 | Koenig Scott | Director | Grant(A) | 40K | — | $0 |
| Mar 29, 2024 | Junius Daniel M | Director | Grant(A) | 5K | $3.00 | $16K |
| Mar 29, 2024 | Goldberg Mark Alan | Director | Grant(A) | 5K | $3.00 | $14K |
| Mar 29, 2024 | King Rachel K. | Director | Grant(A) | 3K | $3.00 | $10K |
| Jan 12, 2024 | Rath Chinmaya | SVP and Chief Business Officer | Grant(A) | 250K | — | $0 |
| Jan 12, 2024 | Johnson Bruce S | SVP & Chief Commercial Officer | Grant(A) | 250K | — | $0 |
| Jan 12, 2024 | Semerjian Harout | Chief Executive Officer, Director | Grant(A) | 695K | — | $0 |
| Jan 12, 2024 | Rock Edwin | Chief Medical Officer | Grant(A) | 250K | — | $0 |
| Jan 12, 2024 | Hahn Brian M. | SVP Finance, CFO | Grant(A) | 250K | — | $0 |
| Dec 29, 2023 | Andrews Patricia S | Director | Grant(A) | 5K | $2.36 | $12K |
| Dec 29, 2023 | King Rachel K. | Director | Grant(A) | 4K | $2.36 | $10K |
| Dec 29, 2023 | Goldberg Mark Alan | Director | Grant(A) | 6K | $2.36 | $14K |
| Sep 30, 2023 | King Rachel K. | Director | Grant(A) | 7K | $1.50 | $10K |
| Sep 30, 2023 | Goldberg Mark Alan | Director | Grant(A) | 9K | $1.50 | $14K |
| Sep 30, 2023 | Andrews Patricia S | Director | Grant(A) | 8K | $1.50 | $12K |
| Sep 22, 2023 | Rock Edwin | Chief Medical Officer | Buy(P) | 30K | $1.38 | $42K |
| Sep 21, 2023 | Rock Edwin | Chief Medical Officer | Buy(P) | 35K | $1.38 | $48K |
| Jun 1, 2023 | Koenig Scott | Director | Option exercise(M) | 21K | — | $0 |
| Jun 1, 2023 | Koenig Scott | Director | Option exercise(M) | 21K | $0.60 | $13K |
| May 19, 2023 | Koenig Scott | Director | Grant(A) | 35K | — | $0 |
| May 19, 2023 | King Rachel K. | Director | Grant(A) | 35K | — | $0 |
| May 19, 2023 | Junius Daniel M | Director | Grant(A) | 35K | — | $0 |
| May 19, 2023 | Goldberg Mark Alan | Director | Grant(A) | 35K | — | $0 |
| May 19, 2023 | Pearson Timothy R | Director | Grant(A) | 35K | — | $0 |
| May 19, 2023 | Andrews Patricia S | Director | Grant(A) | 35K | — | $0 |
| May 19, 2023 | Jackson Scott Thomas | Director | Grant(A) | 35K | — | $0 |
| May 17, 2023 | Hahn Brian M. | SVP Finance, CFO | Sell(S) | 4K | $1.95 | $7K |
| May 10, 2023 | Junius Daniel M | Director | Buy(P) | 30K | $1.56 | $47K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Crescent Biopharma, Inc., SEC CIK 0001253689. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under GLYC and shows every filing by that issuer (also filed as CBIO).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-16. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for GLYC